NCT04963088 2025-06-26
TALENT
The First Affiliated Hospital with Nanjing Medical University
Phase 1/2 Completed
Clinical Trials
19 trialsNCT06573424 2025-05-01
Tirellizumab+Anlotinib VS Anlotinib for MSS-type CRC
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Completed
NCT05021328 2025-02-07
Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC
Hubei Cancer Hospital
Phase 1 Completed
NCT04996758 2024-12-12
Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)
Sun Yat-sen University
Phase 2 Completed
NCT04691388 2024-12-05
A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor
Zhejiang Cancer Hospital
Phase 2 Completed
NCT04770688 2024-08-15
AUTOMAN
Shanghai Chest Hospital
Phase 1/2 Completed
NCT05493995 2024-05-09
PAAG
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Completed
NCT04271813 2024-04-23
Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)
Shanghai Changzheng Hospital
Phase 2 Completed
NCT04967079 2024-04-23
Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients
Shanghai Chest Hospital
Phase 1 Completed
NCT06367010 2024-04-16
Clinical Efficacy of 125I Brachytherapy Combined With Anlotinib in Radioiodine Refractory Thyroid Carcinoma Patients
Jiangxi Provincial Cancer Hospital
Completed
NCT03906058 2023-10-25
Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy
Sun Yat-sen University
Phase 2 Completed
NCT04790409 2023-09-14
Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations
Zhejiang Cancer Hospital
Phase 2 Completed
NCT06015035 2023-08-29
Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer
Tang-Du Hospital
Phase 2 Completed
NCT03743129 2023-06-12
ALTER-L029
Peking University Cancer Hospital & Institute
Phase 2 Completed
NCT05130515 2023-01-31
CC-ANNIE
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Completed
NCT05206656 2022-11-23
Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer
Hunan Cancer Hospital
Phase 2 Completed
NCT04507906 2022-06-28
Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC
Shanghai Chest Hospital
Phase 1/2 Completed
NCT05303740 2022-03-31
Anlotinib Retrospective Study for Esophageal Cancer
The First Affiliated Hospital of Zhengzhou University
Completed
NCT03736837 2021-03-15
ALTER-L004
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Completed